CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D001927: Brain Diseases NIH

(Synonyms: Brain Diseases)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (15)


Name (Synonyms) Correlation
drug380 Baricitinib or Anakinra Wiki 0.50
drug2287 Pulse oximetry Wiki 0.50
drug1583 Local standard of care Wiki 0.50
drug948 EEG Wiki 0.50
drug2472 Ruxolitinib 5 MG Wiki 0.50
drug611 Cannabis, Medical Wiki 0.50
drug586 CT-scan Wiki 0.50
drug2573 Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX] Wiki 0.50
drug957 EP Wiki 0.50
drug2237 Problem-solving and relationship improvement intervention. Wiki 0.50
drug700 Cognitive and behavioral intervention. Wiki 0.50
drug1130 Follow up Wiki 0.35
drug454 Blood tests Wiki 0.35
drug703 Colchicine Wiki 0.32
drug3477 standard therapy Wiki 0.29

Correlated MeSH Terms (26)


Name (Synonyms) Correlation
D020196 Trauma, Nervous System NIH 0.50
D000070627 Chronic Traumatic Encephalopathy NIH 0.50
D000690 Amyotrophic Lateral Sclerosis NIH 0.50
D016472 Motor Neuron Disease NIH 0.50
D005879 Tourette Syndrome NIH 0.50
D012640 Seizures NIH 0.35
D000755 Anemia, Sickle Cell NIH 0.35
D001714 Bipolar Disorder NIH 0.35
D005356 Fibromyalgia NIH 0.29
D003693 Delirium NIH 0.25
D010300 Parkinsonian NIH 0.25
D003424 Crohn Disease NIH 0.22
D000070642 Brain Injuries, Traumatic NIH 0.19
D015212 Inflammatory Bowel Diseases NIH 0.19
D059350 Chronic Pain NIH 0.18
D001930 Brain Injuries, NIH 0.17
D012598 Scoliosi NIH 0.15
D009103 Multiple Sclerosis NIH 0.14
D016638 Critical Illness NIH 0.13
D040921 Stress Disorders, Traumatic NIH 0.10
D014947 Wounds and Injuries NIH 0.10
D013313 Stress Disorders, Post-Traumatic NIH 0.09
D004194 Disease NIH 0.09
D013577 Syndrome NIH 0.05
D045169 Severe Acute Respiratory Syndrome NIH 0.02
D018352 Coronavirus Infections NIH 0.02

Correlated HPO Terms (8)


Name (Synonyms) Correlation
HP:0001298 Encephalopathy HPO 1.00
HP:0006802 Abnormal anterior horn cell morphology HPO 0.50
HP:0007354 Amyotrophic lateral sclerosis HPO 0.50
HP:0100754 Mania HPO 0.35
HP:0001250 Seizure HPO 0.29
HP:0100280 Crohn's disease HPO 0.22
HP:0002037 Inflammation of the large intestine HPO 0.19
HP:0012532 Chronic pain HPO 0.18

There are 4 clinical trials

Clinical Trials


1 Outcomes Mandate National Integration With Cannabis as Medicine

This will be a multistate, multicenter clinical study to determine the efficacy and safety of medical cannabis for a wide variety of chronic medical conditions.

NCT03944447 Chronic Pain Chronic Pain Syndrome Chronic Pain Due to Injury Chronic Pain Due to Trauma Fibromyalgia Seizures Hepatitis C Cancer Crohn Disease HIV/AIDS Multiple Sclerosis Traumatic Brain Injury Sickle Cell Disease Post Traumatic Stress Disorder Tourette Syndrome Ulcerative Colitis Glaucoma Epilepsy Inflammatory Bowel Diseases Parkinson Disease Amyotrophic Lateral Sclerosis Chronic Traumatic Encephalopathy Anxiety Depression Insomnia Autism Opioid-use Disorder Bipolar Disorder Covid19 SARS-CoV Infection Drug: Cannabis, Medical
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Fibromyalgia Crohn Disease Inflammatory Bowel Diseases Parkinson Disease Multiple Sclerosis Brain Injuries Brain Injuries, Traumatic Seizures Motor Neuron Disease Amyotrophic Lateral Sclerosis Brain Diseases Tourette Syndrome Chronic Traumatic Encephalopathy Anemia, Sickle Cell Disease Syndrome Sclerosis Chronic Pain Stress Disorders, Traumatic Bipolar Disorder Stress Disorders, Post-Traumatic Wounds and Injuries
HPO:Abnormal anterior horn cell morphology Amyotrophic lateral sclerosis Bilateral tonic-clonic seizure Bipolar affective disorder Chronic pain Crohn's disease Encephalopathy Focal-onset seizure Generalized-onset seizure Inflammation of the large intestine Mania Seizure

Primary Outcomes

Description: The primary objective is to assess the efficacy and safety of medical cannabis as medicine for treatment of chronic pain and other chronic debilitating diseases. Pain will be measured by Brief Pain Inventory (BPI) numeric scale. Change from baseline in BPI will be assessed at 3-month intervals. For prospective associations between cannabis use and outcomes, use of a lagged mixed-effects models will examine temporal associations between cannabis use and pain severity, opioid sparing, and patient satisfaction. Data will be analyzed from baseline and the annual follow-up waves.

Measure: Treatment of Symptoms

Time: Five years

Description: Incidence of Treatment-Related Adverse Events will be measured by Physician Global Assessment (PGA) numeric scale. Number of participants with Treatment-Related Adverse Events will be assessed by CTCAE v4.0.

Measure: Monitoring Adverse Events

Time: Five years

Secondary Outcomes

Description: Secondary objectives include evaluating increases or decreases in quality of life, and increases or decreases in concomitant opioid use. Satisfaction with treatment will be measured by a Visual Analog Score (VAS). Change From baseline in Satisfaction with treatment measured by (VAS) be assessed at 3-month intervals.

Measure: Cannabis Impact on Quality of Life

Time: Five years

Description: Tertiary objectives will examine preferences for routes of administration, and preferences for THC / CBD ratios. Categorical factors will be summarized using frequencies and percentages, while continuous measure distributions will be described using means, standard deviations, and quartiles of interest.

Measure: Cannabis Route and Dosing

Time: Five years

2 Outcomes in Patients With Acute Encephalopathy and SARS-Cov-2 Infection

Infection with SARS-CoV-2 or severe acute respiratory syndrome coronarvirus type 2 was highlighted in December 2019 in the city of Wuhan in China, responsible for an pandemic evolution since March 11, 2020. The infection affects all ages of life, although affecting children in a very small proportion of cases. The typical presentation of the disease combines fever (98%), cough (76%), myalgia and asthenia (18%) as well as leukopenia (25%) and lymphopenia (63%). Upper airway involvement rare. The main clinical presentation requiring hospitalization of infected patients is that of atypical pneumonia which may require critical care management (27%), and progress to an acute respiratory distress syndrome (67%) involving life-threatening conditions in almost 25% of patients diagnosed with SARS-CoV-2 infection. Other organ damage have been reported, mainly concerning kidney damage (29%) which may require renal replacement therapy in approximately 17% of patients. Neurological damage has been very rarely studied, yet reported in 36% of cases in a study including patients of varying severity. Finally, the mortality associated with this emerging virus is high in patients for whom critical care management is necessary, reported in 62% of patients. We therefore propose a prospective observational study which aim at reporting the prevalence of acute encephalopathy at initial management in Critical/Intensive care or Neurocritical care , to report its morbidity and mortality and to identify prognostic factors.

NCT04320472 COVID-19 Encephalopathy Critically Ill Other: Follow up
MeSH:Brain Diseases Critical Illness
HPO:Encephalopathy

Primary Outcomes

Description: ratio of patients with acute encephalopathy among the total of patients with SARS-Cov-2 infection at Critical/Intensive care or Neurocritical care admission

Measure: prevalence

Time: at Critical/Intensive care or Neurocritical care admission

Secondary Outcomes

Description: A favorable outcome is defined by a Glasgow Outcome Scale (GOS) of 5. The Glasgow Outcome Scale (GOS) will be determined patients charts review, phone call, and/or general practitioner interview conducted by an independent assessor. The GOS score : [1: Death, 2: Persistent vegetative state, 3: Severe disability, 4: Moderate disability, 5 : Low disability]

Measure: Favorable outcome

Time: 3 months

Description: A favorable outcome is defined by a Glasgow Outcome Scale Extended (GOSe) >= 5. The Glasgow Outcome Scale Extended (GOSe) will be determined patients charts review, phone call, and/or general practitioner interview conducted by an independent assessor. The GOSe score : [1: Death, 2: Persistent vegetative state, 3: Severe disability Lower, 4: Severe disability Upper, 5: Moderate disability Lower, 6: Moderate disability Upper, 7 : Good recovery lower, 8 : Good recovery Upper]

Measure: Favorable outcome

Time: 3 months

3 Biomarker-guided Assessment of Neurocognitive Impairment in Patients With COVID-19 - a Multicenter Case-control Study

Delirium and acute neurocognitive impairment are increasingly observed in adult and pediatric patients with COVID-19. Prospective clinical studies combining clinical and laboratory examinations including specific biomarkers of neuroaxonal injury were not performed for COVID-19. The value of biomarkers of neuroaxonal injury was proven in preliminary studies. These biomarkers could thus contribute to the systematic detection of neurocognitive impairment in patients with COVID-19. Due to worldwide increasing numbers of hospitalized patients with COVID-19, biomarkers of neuroaxonal injury are highly valuable to detect and monitor cognitive impairment, especially with regard to limited resources available to perform time-consuming brain imaging. Biomarkers of neuroaxonal injury are therefore not only of great interest to detect neurocognitive impairment but also to quantify the severity of brain injury in patients with COVID-19.

NCT04359914 Critical Illness COVID-19 Central Nervous System Injury Delirium Encephalopathy
MeSH:Delirium Brain Diseases Trauma, Nervous System Critical Illness
HPO:Encephalopathy

Primary Outcomes

Description: Assessment of neurocognitive impairment using validated tools

Measure: Incidence of delirium/neurocognitive impairment in adult and pediatric patients with COVID-19 compared to patients without COVID-19

Time: Day 90

Description: Measurement of biomarker levels (e.g. NSE, S100B, neurofilament proteins) derived from blood samples

Measure: Change in neuroaxonal injury biomarker levels in patients with COVID-19 compared to patients without COVID-19

Time: Change from baseline biomarker levels at day 28

Description: Assessment of the neurocognitive performance of patients using validated tests (e.g. Short Blessed Test)

Measure: Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19

Time: Day 90

Description: Assessment of the change in the neurocognitive performance of patients using validated tests (e.g. IQCODE)

Measure: Neurocognitive 3-months outcome in patients with COVID-19 compared to patients without COVID-19

Time: Change from baseline IQCODE results at day 90

Secondary Outcomes

Description: Assessment of the overall quality of life using validated tests [e.g. Modified Rankin Scale with a range from 0 (no symptoms) to 6 (dead)]

Measure: Quality of life in patients with COVID-19 compared to patients without COVID-19 after hospital discharge

Time: Day 90

Description: Cumulative days in hospital

Measure: Length of hospital stay in patients with COVID-19 compared to patients without COVID-19

Time: 1 year

Description: Survival after 90 days

Measure: 90-day survival in patients with COVID-19 compared to patients without COVID-19

Time: Day 90

4 Determination of Acute Encephalopathy Predictors in Patients With COVID-19

The SARS-CoV-2 infection was detected in December 2019 in Wuhan City, China. The infection affects all age groups, although childhood is the lowest proportion of those affected. The main clinical manifestations that require hospitalization of infected patients are SARS pneumonia, which may require treatment in the intensive care unit (27%) and its progression into acute respiratory distress syndrome (67%) with life-threatening conditions in almost 25% of patients diagnosed with "SARS-CoV-2 infection". Nervous system damage with SARS-CoV-2 infection has been practically not investigated, but neurological disorders have been reported in 36% of these patients. Finally, the mortality rate associated with the new virus is high in patients who require treatment in intensive care units (62% of cases). Therefore, we are conducting a prospective study to identify acute encephalopathy predictors in patients with COVID-19.

NCT04405544 Encephalopathy COVID Diagnostic Test: CT-scan Diagnostic Test: EEG Diagnostic Test: EP Diagnostic Test: Pulse oximetry Diagnostic Test: Blood tests
MeSH:Brain Diseases
HPO:Encephalopathy

Primary Outcomes

Description: The percentage of patients who have developed encephalopathy

Measure: The percentage of patients who have developed encephalopathy

Time: 10 days


HPO Nodes


HP:0001298: Encephalopathy
Genes 351
CHEK2 DNM1 ASNS KMT2E NDUFAF5 CHD2 GLUL SYNJ1 SUCLA2 ATP6V1A SCN3A AMACR RANBP2 SLC25A13 SLC13A5 COX1 SLC22A5 TSFM SCN8A ND2 ACTL6B RNASEH2C SLC6A9 NUS1 SPTAN1 CLP1 TRNF CNKSR2 NADK2 TREX1 PARS2 GABRB3 DPM2 ND3 SLC1A2 PCCB GRIN1 ARV1 ADAM22 CPLX1 ATP6V1A NDUFAF1 NDUFV2 BOLA3 GPR35 CHD2 SLC1A2 GCDH KCNT1 TRAK1 TRNC COG8 NEUROD2 SCN8A ATP1A3 HADH PNPT1 SYNJ1 HADH CDKL5 MEF2C COQ2 WWOX ACY1 DHDDS TRNK TRNL1 ND1 ND4 HNRNPU TRAK1 PPP3CA NDUFS3 TUFM CNPY3 BSCL2 NDUFV2 SCN1A ATP5F1A CAD HIBCH EEF1A2 SIK1 SERPINI1 CYC1 NTRK2 NAXD WDR45 TCF4 COX3 TRNQ KCNB1 GABRB1 FADD FADD HCN1 DENND5A SLC25A1 GABRA2 GBA NDUFB11 NDUFS1 GCSH PIGP ALG9 CACNA1A MDH2 NECAP1 DLD TBCD RNASEH2B NRXN1 CYTB PCCA TRNV LIPT2 CUX2 TIMMDC1 NDUFAF8 NDUFB10 CACNA1B HTRA1 WWOX TRAPPC12 COX3 TIMM50 NADK2 UNC80 SERAC1 COQ4 UGDH AP2M1 PIGA KCNQ2 SLC25A20 FCSK ATP5F1D MST1 PMPCB CUX2 NDUFS6 FOXRED1 GLDC NBAS SZT2 NDUFA11 XIAP KYNU TRNS2 ND1 CYFIP2 GALC NDUFS4 NDUFAF4 TRNQ DOCK7 MDM2 SLC19A3 TRNK PNPO CPT2 ACAD9 COQ9 AP3B2 EEF1A2 PNKP TRNS1 KCNB1 CYFIP2 TCF4 GRIN2D CLPB COG8 NDUFB3 SLC12A3 STAG1 STXBP1 TRNH NDUFS8 NAGS NDUFAF3 LIAS FGF12 NDUFAF4 TMEM126B NUS1 NDUFAF2 CACNA1A GLYCTK TBC1D24 MECP2 ETHE1 CCDC88A DNM1 SCN2A BSCL2 NTRK2 GABRG2 GRIN2D KCNQ2 DNM1 CPT1A CLCN4 COX2 TRNF RNF13 GBA GABRA1 TRNW GABRB2 GCDH SLC6A1 SLC2A1 SLC25A22 CLTC TGFB1 DGUOK PNPO ARHGEF9 GABRG2 ITPA ROGDI ATAD1 CLCNKB TK2 CACNA2D2 CACNA1E NECAP1 ZNHIT3 KCNQ5 NDUFA6 SZT2 NRXN1 NDUFA6 LYRM7 SLC25A15 NDUFS6 FBLN1 D2HGDH PRNP TBCE TMEM70 TSEN54 AARS1 STXBP1 IBA57 NDUFS3 UBA5 SUCLG1 NDUFS2 STAT2 NDUFV1 ARV1 TRNS2 GUF1 GNAO1 TBCK PACS2 PCK1 AP3B2 ACSF3 ATP5F1A CARS2 NDUFS4 YWHAG COX1 CDKN2A SH2D1A TWNK GLS TRNW CHD2 DNM1L ND5 NDUFA1 ARX PARS2 SLC25A15 NDUFA11 PLCB1 SLC19A3 MPC1 TBCE RANBP2 ND6 TP53 TH SLC35A1 KCNA2 ND5 CARS2 SLC22A5 HMGCL NDUFAF1 SYNGAP1 PPP3CA FBXL4 GABRB2 CNTNAP2 KCNT2 NDUFAF2 COX15 ARHGEF9 NAXE BCS1L ACY1 CACNA1B KYNU DLD TBC1D24 NDUFB3 GPT2 FRRS1L GRIN2B GABRB3 SCN1A TRNS1 NDUFB9 ST3GAL3 COX2 SLC25A22 FGF12 SLC13A5 DHDDS ACAD9 ETHE1 SLC35A2 PSAP GABRA5 UGT1A1 KCNA2 SCN1B MAPK10 UBA5 SIK1 KCNA2 HCN1 SLC25A12 SCN3A AMT ND6 NDUFS7 AARS1 TRNL1 SYNGAP1 NDUFS7 GABBR2 TRIT1 ND1 PHACTR1 NUBPL
Protein Mutations 1
A3243G
SNP 0